News

Acerta Pharma has operations in Oss, the Netherlands and several US sites. The US headquarters is in Redwood City, California. The deal gives AstraZeneca access to Acerta’s lead

Filgotinib is a JAK1 inhibitor discovered and developed by Galapagos using its target and drug discovery technology platform. It has been developed to treat rheumatoid arthritis (RA) and

Using the Sinequa Platform, UCB is able to more effectively find data sets that will help expedite responding to questions arising in the lifecycle of drug development, in

By combining CapellaBio’s SMarTR computational analysis platform with SCT’s iPSC-derived cardiomyocyte discovery platform, advanced drug leads have been identified in the first of a series of programs. Cancer

The study met its primary endpoint of improving progression-free survival (PFS) compared with dacarbazine treatment. The median PFS on the binimetinib arm was 2.8 months versus 1.5 months

Arsia and Biogen will focus on providing meaningful treatment administration improvements for hemophilia patients by enabling subcutaneous versions of treatments that are currently administered via intravenous infusion. The

Basaglar is indicated to improve glycemic control in adult and pediatric patients with type 1 diabetes and adults with type 2 diabetes. It is considered as a biosimilar

The agency has set 15 June 2016 as the action date for Vaxchora BLA. If approved, it would become the only anti-cholera vaccine in the US. PaxVax’s BLA

The company has forged an alliance with Chinese biologics firm WuXi AppTec to produce new biological drugs in the country. AstraZeneca has the option to acquire WuXi AppTec’s